Altin Biosciences creates first‑in‑class, non‑hormonal botanical drug candidates to address unmet medical needs, focusing on uterine fibroids. Its lead candidate, ABC‑105/205, combines the natural compounds crinum latifolium (Crila®) and epigallocatechin gallate (EGCG) to shrink or eliminate fibroids while remaining fertility‑ and pregnancy‑friendly, offering a drug‑based alternative to invasive surgery. The program is advancing through pre‑clinical and clinical studies under FDA regulation.
Funding
Funding not disclosed
Founders
Product
Problem
Uterine fibroids affect a large proportion of women of reproductive age, causing heavy, painful periods, anemia, and reduced fertility. Current management often relies on hormonal therapies or invasive surgeries such as myomectomy and hysterectomy, which carry significant recovery time, risk of complications, and may compromise future pregnancy.
Solution
Altin Biosciences is developing ABC‑105/205, a first‑in‑class, non‑hormonal botanical drug that combines a standardized extract of Crinum latifolium (Crila®) with epigallocatechin gallate (EGCG). Pre‑clinical studies demonstrate synergistic antiproliferative and pro‑apoptotic activity against human uterine fibroid cells, suggesting the ability to shrink or eliminate fibroids. The formulation is designed to be compatible with fertility and pregnancy, offering a medical alternative to surgical removal. The candidate follows the FDA’s Botanical Drug Guidance, positioning it for a regulated approval pathway. Ongoing pre‑clinical and planned clinical trials will evaluate safety, efficacy, and reproductive outcomes before market entry.
Target Audience
Primary customers are women of reproductive age diagnosed with uterine fibroids and their healthcare providers—including gynecologists and reproductive endocrinologists—seeking a non‑surgical, fertility‑preserving treatment option.
Features
- Patent‑pending combination of Crila® (Crinum latifolium) and EGCG delivering synergistic antiproliferative and apoptosis effects on fibroid tissue
- Non‑hormonal mechanism of action, reducing risk of hormone‑related side effects
- Designed to be fertility‑ and pregnancy‑friendly, supporting reproductive health
- Developed under FDA botanical drug regulations, enabling a defined regulatory pathway
- Pre‑clinical data published in a peer‑reviewed journal showing superior efficacy versus single‑agent treatments
- Planned clinical trial program to assess safety, fibroid reduction, and reproductive outcomes